At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
bicalutamide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study
In Brief
A Phase 2 clinical trial evaluating bicalutamide, diagnostic laboratory biomarker analysis, and 1 other intervention for Breast Cancer. Completed, enrolled 28 participants across 8 sites.
Detailed Summary
RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), AstraZeneca
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMay 2007
Primary CompletionJun 2021
TodayJul 2026
First PostedMay 3, 2007
Enrollment StartMar 23, 2007
Primary CompletionJun 24, 2021
TodayJul 2, 2026
Enrollment to primary: 14.3 yearsPosted 19.2 years ago
Interventions
bicalutamidedrug
diagnostic laboratory biomarker analysisother
immunohistochemistry staining methodother